Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
10.9758/cpn.2019.17.2.297
- Author:
Alyna TURNER
1
;
John J MCGRATH
;
Olivia M DEAN
;
Seetal DODD
;
Andrea BAKER
;
Susan M COTTON
;
James G SCOTT
;
Bianca E KAVANAGH
;
Melanie M ASHTON
;
Adam J WALKER
;
Ellie BROWN
;
Michael BERK
Author Information
1. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Barwon Health, Geelong, Australia. a.turner@deakin.edu.au
- Publication Type:Randomized Controlled Trial
- Keywords:
Mangosteen;
Garcinia mangostana Linn.;
Schizophrenia;
Psychotic disorder;
Treatment clinical trial;
Oxidative stress
- MeSH:
Cognition;
Depression;
Fruit;
Garcinia mangostana;
Garcinia;
Inflammation;
Neurogenesis;
Outcome Assessment (Health Care);
Oxidation-Reduction;
Oxidative Stress;
Psychopathology;
Psychotic Disorders;
Schizophrenia;
Synaptic Transmission;
Xanthones
- From:Clinical Psychopharmacology and Neuroscience
2019;17(2):297-307
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double-blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. METHODS: We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. RESULTS: Ethical and governance approvals were gained and the trial commenced. CONCLUSION: A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.
